Loading...

Advanced Therapies And Asia Pacific Markets Will Expand Global Scope

Published
06 Aug 24
Updated
07 May 25
AnalystConsensusTarget's Fair Value
US$124.53
19.8% undervalued intrinsic discount
10 Sep
US$99.87
Loading
1Y
19.6%
7D
-7.6%

Author's Valuation

US$124.5

19.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Increased 7.78%

Shared on30 Apr 25
Fair value Decreased 3.66%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 0.42%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.0% to 0.0%.

Shared on16 Apr 25
Fair value Decreased 0.38%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 4.47%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 0.27%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Decreased 1.27%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.